Country: Malta
Language: English
Source: Medicines Authority
IMATINIB
BioOrganics BV Microweg 22, 6545CM Nijmegen, Netherlands
L01XE01
IMATINIB 400 mg
FILM-COATED TABLET
IMATINIB 400 mg
POM
ANTINEOPLASTIC AGENTS
Withdrawn
2013-04-08
Page 1 of 8 PACKAGE LEAFLET: INFORMATION FOR THE USERRead the complete document imatinib _ _ READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Imatinib BioOrganics is and what it is used for 2. What you need to know before you take Imatinib BioOrganics 3. How to take Imatinib BioOrganics 4. Possible side effects 5. How to store Imatinib BioOrganics 6. Contents of the pack and other information 1. WHAT IMATINIB BIOORGANICS IS AND WHAT IT IS USED FOR Imatinib is a medicine containing an active substance called imatinib . This medicine works by inhibiting the growth of abnormal cells in the diseases listed below. These include some types of cancer. IMATINIB IS A TREATMENT FOR ADULTS AND CHILDREN FOR: • CHRONIC MYELOID LEUKAEMIA (CML). Leukaemia is a cancer of white blood cells. These white cells usually help the body to fight infection. Chronic myeloid leukaemia is a form of leukaemia in which certain abnormal white cells (named myeloid cells) start growing out of control. In adults Imatinib is used to treat a late stage of chronic myeloid leukaemia called “blast crisis”. In children and adolescents, however, it may be
Page 1 of 31 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCTRead the complete document 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 100 mg imatinib (as mesilate). Each film-coated tablet contains 400 mg imatinib (as mesilate). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. 100 mg tablet: brown, round (9 mm), biconvex tablets, scored on one side and debossed on the other side with ‘I9AB 100’. 400 mg tablet: brown, oblong (10 x 18 mm), biconvex tablets and debossed on one side with ‘I9AB 400’. <100 mg> The tablet can be divided into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Imatinib is indicated for the treatment of • paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. • paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. • adult patients with Ph+ CML in blast crisis. • adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. • adult patients with relapsed or refractory Ph+ ALL as monotherapy. • adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. • adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1- PDGFRα rearrangement. The effect of Imatinib on the outcome